Rafael Fonseca: Anitocel presented 40 enrolled and 38 dosed

Rafael Fonseca shared a post on X:

“Anitocel presented 40 enrolled and 38 dosed. 100M cells. Prior LOT 5-4. ORR 100% 76% CR or better, across all groups. Median PFS not reached at 2 years. Not even in EMD group. No clear HR genetics influence ORR. No MNT. iMMagjne-3 trial similar to CARTITUDE-4”

Source: Rafael Fonseca/X

Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing in multiple myeloma and related conditions. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment. He has led research on genetic markers in myeloma. Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.